evidence and practice
An observational study of the effect of dilution and delivery speed on the development of phlebitis after epirubicin chemotherapy
Joanne Wiltshire Registered nurse, Velindre Cancer Centre, Main Outpatients, Cardiff, Wales
Rosie Roberts Chemotherapy specialist nurse, Velindre Cancer Centre, Cardiff, Wales
Aim Epirubicin causes venous irritation when administered through a peripheral cannula. The aim of this study was to identify if the speed of administration and/or volume of 0.9% saline used during epirubicin administration influences the development of chemical phlebitis in patients with breast cancer.
Method Perceptions of 27 chemotherapy nurses of how administration technique may influence development of chemical phlebitis were collated from a questionnaire. Between August 2017 and May 2018, 120 cycles of epirubicin were observed and administration speed and volume of saline used during administration were recorded. Phlebitis signs and symptoms were graded by staff using a phlebitis severity scale and patients completed a questionnaire.
Results Most chemotherapy nurses believed that administering a large volume of fluid during epirubicin and flushing afterwards were helpful in preventing phlebitis, but there was no consensus on the benefits of rapid or slow infusion speeds. Observation data analysed using SPSS v24 demonstrated no significant influence on the severity of phlebitis for administration speed (P=0.617) or volume of saline (P=0.879). Administration pain was associated with a significantly higher incidence of phlebitis (P=0.001).
Conclusion Ensuring a concentration of <3mg/mL could reduce the risk of pain during administration.
Cancer Nursing Practice. doi: 10.7748/cnp.2019.e1585Peer review
This article has been subject to external double-blind peer review and has been checked for plagiarism using automated softwareCorrespondence
Wiltshire J, Roberts R (2019) An observational study of the effect of dilution and delivery speed on the development of phlebitis after epirubicin chemotherapy. Cancer Nursing Practice. doi: 10.7748/cnp.2019.e1585Acknowledgements
The authors would like to thank the Lowri Pugh Foundation for financial support, Velindre Cancer Centre for funding research nurse time and the support of its chemotherapy nursing team, University of South Wales professor Mark Williams for his support, and all patients involved for their participation
Published online: 13 May 2019
Want to read more?
Subscribe for unlimited access
Try 1 month’s access for just £1 and get:
- Full access to the website and the online archive
- Bi-monthly digital edition
- RCNi Portfolio and interactive CPD quizzes
- RCNi Learning with 200+ evidence-based modules
- 10 articles a month from any other RCNi journal
Already subscribed? Log in
Alternatively, you can purchase access to this article for the next seven days. Buy now